Variation in left ventricular cardiac magnetic resonance normal reference ranges: systematic review and meta-analysis

Zahra Raisi-Estabragh[1, 2], Asmaa A.M. Kenawy[1, 2], Nay Aung[1, 2], Jackie Cooper[1], Patricia B. Munroe[1], Nicholas C. Harvey[3, 4], Steffen E. Petersen[1, 2], Mohammed Y. Khanji[1, 2]

1. William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK

2. Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, West Smithfield, EC1A 7BE, London, UK

3. MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK

4. NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK

Corresponding author:

Zahra Raisi-Estabragh, Address: William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK, E-mail: zahraraisi@doctors.org.uk, Phone number: 00442037658766

Abstract

Aims: To determine population-related and technical sources of variation in cardiac magnetic resonance (CMR) reference ranges for left ventricular (LV) quantification through a formal systematic review and meta-analysis.

Methods and results: This study is registered with the International Prospective Register of Systematic Reviews (CRD42019147161). Relevant studies were identified through electronic searches and assessed by two independent reviewers based on predefined criteria. Fifteen studies comprising 2,132 women and 1,890 men aged 20–91years are included in the analysis. Pooled LV reference ranges calculated using random effects meta-analysis with inverse variance weighting revealed significant differences by age, sex, and ethnicity. Men had larger LV volumes and higher LV mass than women [LV end-diastolic volume (mean difference=6.1ml/m^2, p-value=0.014), LV end-systolic volume (MD=4ml/m^2, p-value=0.033), LV mass (mean difference=12g/m^2, p-value=7.8×10^{-9})]. Younger individuals had larger LV end-diastolic volumes than older ages (20-40years vs ≥ 65years: women MD=14.0ml/m^2, men MD=14.7ml/m^2). East Asians (Chinese, Korean, Singaporean-Chinese, *n*=514) had lower LV mass than Caucasians (women: MD=6.4g/m^2, p-value=0.016; men: MD=9.8g/m^2, p-value=6.7×10^{-5}). Between study heterogeneity was high for all LV parameters despite stratification by population-related factors. Sensitivity analyses identified differences in contouring methodology, magnet strength, and post-processing software as potential sources of heterogeneity.

Conclusion: There is significant variation between CMR normal reference ranges due to multiple population-related and technical factors. Whilst there is need for population stratified reference ranges, limited sample sizes and technical heterogeneity precludes derivation of meaningful unified ranges from existing reports. Wider representation of different populations and standardisation of image analysis is urgently needed to establish such reference distributions.

Keywords: Cardiac magnetic resonance, reference range, normal range, left ventricle

Introduction

Accurate quantification of left ventricular (LV) structure and function is key to clinical decision making in cardiology. LV cavity volumes in end-systole (LVESV) and end-diastole (LVEDV) reflect adverse myocardial remodelling[1]. LV mass (LVM), is an independent prognostic marker in individuals with and without cardiovascular disease[2–4]. LV ejection fraction (LVEF) provides an estimate of LV systolic function and is the determinant of many important clinical decisions such as cardiac-resynchronisation therapy, valve interventions, and management of heart failure syndromes[5–9].

Cardiac magnetic resonance (CMR) is the reference test for cardiac chamber quantification and is increasingly used to guide difficult clinical decisions. However, there is lack of consensus on normal reference ranges with variation in published reports[10]. Whilst there are known sex, age, and ethnic differences in cardiac morphology[11–13], these differences have not been adequately studied with CMR and commonly quoted ranges are based on small cohorts that do not always represent the populations to which they are applied.

Previous attempts to pool results from different CMR reference ranges were limited by the datasets available at the time, with small sample sizes, inability to provide age and ethnicity stratification, or perform a formal meta-analysis[14]. In the last five years, there has been a surge of publications reporting normal CMR reference ranges from around the world. The objective of this study is to determine population-related (sex, age, ethnicity) and technical sources of heterogeneity through a formal systematic review and meta-analysis of published CMR reference ranges.

Methods

This study is registered online with the International Prospective Register of Systematic Reviews (PROSPERO, https://www.crd.york.ac.uk/PROSPERO/; registration number: CRD42019147161). Methods are in accordance with the PRISMA statement (Transparent Reporting of Systematic Reviews and Meta-Analyses, http://prisma-statement.org/). The PRISMA checklist is provided in the Supplementary material.

Selection criteria

We selected studies that defined a normal reference range in healthy adults (>18years-old) with sample sizes of ≥50, reported in the English language. We required confirmation of healthy status of participants, however we allowed some variation in the stringency with which this was defined. We accepted studies with 1.5T or 3T scanners from all vendors. We restricted to studies using steady state free precession (SSFP) sequences, as this reflects current clinical standards for volume quantification. We required LV quantification to be made using short axis cine images using a predefined standard operating procedure for image acquisition and analysis. Studies selected for quantitative analysis were required to report sex stratified LVM, LVEDV, LVESV, and LVEF in a manner where mean and standard deviation values in indexed formats [indexed to body surface area (BSA), denoted by i] could be extracted.

Search strategy

ZRE and AK independently searched Ovid Medline (1946- April 2019) and Embase electronic databases. Relevant subject headings were used to conduct the search using MeSH terms (Medical Subject Headings) for Medline and the equivalent, Emtree, for Embase. Subject headings and their 'trees' were examined, and relevant subheadings were selected, related terms were included using the explode command (Supplementary Table 2). Search terms were combined using Boolean operators. Selected terms were included in the search as keywords. We performed separate keyword search of titles and abstracts to ensure capture of newer publications not yet incorporated into MeSH/Emtree classifications. The final output was limited to studies in adults (>18years-old) and in the English language.

Study selection

Study selection was through a process of title screening, abstract review, and full text review carried out independently by AK and ZRE. At each iteration, results were merged, and duplicates removed. Further studies were identified through reference and author searching. Decision for study eligibility

was based on predefined selection criteria. In case of disagreement, decisions were taken through discussion after review of full text and mediation by MYK.

Quality assessment

As this review was not based on intervention-outcome studies, existing quality assessment tools were not entirely applicable. We therefore designed a quality assessment protocol tailored to our purpose based on revised elements from the ROBINS-I (The Risk Of Bias In Non-randomized Studies – of Interventions) and QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies) assessment tools[15,16].

Data extraction

Mean, standard deviation, and sample size for sex stratified LVMi, LVESVi, LVEDVi, and LVEF were extracted from individual studies. Data extraction was carried out independently by ZRE and AK and cross-checked by ZRE.

Statistical analysis

Statistical analysis was with the 'meta: General package for meta-analysis' package on the R studio platform [R Core Team (2018). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/][17]. We calculated pooled age, sex, and ethnicity specific ranges for LV parameters indexed to BSA. We used random effects meta-analysis of single means with inverse variance weighting to calculate pooled values. Between study heterogeneity was assessed with τ^2, I^2, Q statistic, and the related p-value. For subgroup analysis, mean difference (MD), Q statistic, and p-values are presented. We performed sensitivity analysis with the following variables: scanner vendor, magnet strength, post-processing analysis software, papillary muscles contouring (inclusion/exclusion in LVM). To assess the impact of the larger studies in the meta-analysis on the overall results we display results for both fixed and random effects models in the figures. A large study with extreme results would lose influence under the random effects model. Our analyses demonstrate similar estimates from fixed and random effects

models; therefore we conclude that variations in study sample size are not having a disproportionate impact on the results. For further illustration we performed sensitivity analysis with exclusion of the two largest studies from the pooled estimates, which also did not significantly alter the pooled estimates.

Results

Systematic review

Our approach is summarised in the PRISMA flow diagram (Figure 1). Combined Ovid Medline and Embase searches yielded 859 unique hits; 6 additional citations were obtained from cross-referencing and author searches. After title screening, 112 citations were deemed potentially relevant and selected for abstract review. From these, 27 papers were selected for full text review based on fulfilment of the inclusion criteria. A further 12 studies were excluded after examination of the full text based on quality assessment and consideration of inclusion criteria. Fifteen studies were selected for inclusion in the meta-analysis. Of these, two did not report LVESV, therefore, 13 studies are included in analysis for this parameter.

Quality assessment

Pertinent quality indicators were systematically assessed for studies selected for full text review. There were differences in the definition of "healthy status" with variable use of clinical assessment, blood tests, and non-invasive tests (echocardiography, electrocardiogram) to exclude disease. There were also variations in the number of readers and reports of inter-/intra-observer variability. Overall, the studies included in the meta-analysis are of high quality with clearly defined study objectives and imaging protocols (Supplementary Table 1).

Summary of selected studies

Overall 2,132 women and 1,890 men from 15 studies published between 2003-2018 are included in the analysis (Table 1). The age range is between 20-91years. There are five studies from non-Caucasian cohorts: two from Chinese populations[18,19], and one study each from Singaporean-

Chinese[20], Korean[21], and Brazilian[22] cohorts. There are ten studies from Caucasian populations[23–30]. Both the Chinese studies and the study from Singapore use a 3T scanner, all others use 1.5T scanners. Scanners used included several Siemens and Philips models; one of the earlier studies used a General Electric (GE) scanner. Various versions of a wide range of post-processing software packages were used for endocardial contouring. Contouring technique was either manual or semi-automated with manual edits. Eleven studies included papillary muscles in the LVM, the remainder as part of the blood pool.

Meta-analysis

Stratification by sex

Results for sex-stratified analyses are summarised in Table 2, Figure 2, and Figure 3. Compared to women, men had significantly larger LVEDVi (MD=6.1ml/m^2, p-value=0.014), LVESVi (MD=4.0ml/m^2, p-value=0.033), and LVMi (MD=12.0 g/m^2, p-value=7.8×10^{-9}). LVEF was not significantly different between men and women (MD=-1.5%, p-value 0.33). In both men and women, there was significant between-study heterogeneity for all LV parameters (I^2 >97% for all).

Stratification by age and sex

Three age categories were created to represent young (20-40 years), middle aged (40-65 years), and older (≥65 years) adults. These age cut-offs allowed inclusion of the largest possible pooled sample from all studies. Age and sex stratified results are presented in Supplementary Table 3. Both men and women had significantly larger LVEDVi in younger age (Supplementary Figure 1) with similar magnitude of difference (20-40 years vs ≥ 65years: women MD=14.0 ml/m^2, men MD=14.7 ml/m^2). A trend for larger LVESVi in younger age is observed for both men and women, but is not statistically significant in either. There were non-significant trends towards greater LVMi in younger and higher LVEF in older individuals. The data available did not permit analysis with age as a

continuous measure or with more granular age bands. Between-study heterogeneity remained high after sex and age stratification.

Stratification by sex and ethnicity

Pooled values were calculated for two ethnicity categories: East Asian (Chinese, Singaporean-Chinese, Korean) and Caucasian (including non-Aboriginal Australian). East Asian men and women had significantly lower LVMi compared to Caucasians (women: MD=6.4g/m^2, p-value=0.016; men: MD=9.8g/m^2, p-value=6.7 $\times 10^{-5}$), this difference was more consistent and of greater magnitude in men (Supplementary Figure 2). Again, there was high statistical heterogeneity between studies. Further comparison was made between pooled values for Caucasians, East Asians, and the one Brazilian cohort. Again, significant subgroup differences were observed in LVMi for both men and women. Brazilian men and women had greater LVMi than East Asians, but lower values than Caucasians. There were no significant ethnic differences in any of the other LV parameters (Supplementary Table 4). We present pooled sex stratified results for Caucasians and East Asians with addition of age stratification for Caucasians (Figure 4, Figure 5). We cannot provide pooled age and sex stratified results for East Asians due to variation in age bands and reporting of stratified results in the original studies.

Sensitivity analyses

To explore other potential sources of between-study heterogeneity, sensitivity analyses were performed with the following variables: scanner vendor, field strength, post-processing software, and papillary muscle contouring (included vs excluded from LVM) (Supplementary Table 5). Studies including papillary muscles as part of the LVM reported significantly higher LVM for both men (MD=7.1g/m^2, p-value=0.017) and women (MD=6.0g/m^2, p-value=0.029). Despite stratification for

sex and contouring methodology, heterogeneity between studies remained high, with greater heterogeneity for studies contouring papillary muscles as part of LVM (Supplementary Figure 3). The post-processing software used for contouring also impacted results with Argus software from Siemens Medical yielding significantly smaller LVESVi and higher LVMi in comparison to other post-processing tools. We also note a significant relationship between lower LVMi and 3T field strength scanners. Limited samples and significant methodological heterogeneity at all levels meant that pooling of results with stratification for multiple technical and population related factors was not possible.

Discussion

Summary of findings

We present the first formal systematic review and meta-analysis of CMR normal reference ranges incorporating results from 1,890 men and 2,132 women from 15 studies. Pooled results demonstrate significant differences in LV parameters by sex, age, and ethnicity. Compared to women, men had larger cavity volumes and greater LVMi. Younger individuals had larger LV volumes, higher LVMi and lower LVEF in comparison to older ages. Individuals with East Asian ancestry had lower LVMi in comparison to Caucasians. Between-study heterogeneity was high for all parameters despite stratification for population-related factors. Sensitivity analyses identified differences in contouring methodology, post-processing software, and magnet field strength as significant contributors to the observed between-study heterogeneity. Limited sample sizes from existing results and methodological variation at all levels precludes recommendation of robust unified reference ranges from this analysis.

Comparison with previous literature

The observed sex, age, and ethnic differences in LV measures are consistent with previous reports using cardiac computed tomography, echocardiography, and gradient echo CMR[31–35].

Echocardiography studies report important differences in cardiac morphology of healthy individuals

of South Asian and Afro-Caribbean ethnicity in comparison to Caucasians[32,36,37]. Further, there are reports of differential impact of alterations in LV parameters in different ethnic populations. For instance, Akintoye et al. report greater prognostic utility of LVMi for predicting cardiovascular events for Chinese and Hispanic populations in comparison to non-Hispanic Whites[38]. Similarly, there are reports of significant ethnic differences in ventricular remodelling in response to important cardiovascular risk factors such as hypertension[36]. As ethnic differences exist for LV parameters, it is likely that there are also ethnic differences in the morphology of other cardiac structures such as the right ventricle and the atria. Whilst in recent years, there have been reports of CMR references ranges from several non-Caucasian cohorts, data from a wide range of ethnicities remains absent, as such, our understanding of ethnic differences in CMR derived measures of cardiac morphology remains incomplete.

In addition to the expected variations by population-related factors, we identified important technical sources of heterogeneity. We identified magnet strength (3T vs 1.5) as a significant source of variation, in particular lower LVMi reported by the studies using 3T scanners. Certainly, it is conceivable that higher spatial resolution produced by expert programming of pulse sequences with 3T scanners provides superior endocardial border definition and thus more accurate contouring of the LV endocardium with exclusion of an intracavity trabecular layer that may be included within LVM at lower spatial resolutions. However, there are other factors that need consideration, for instance, the 3T studies are all more recent publications (2016 onwards) and image analysis for these studies has been conducted with modern post-processing software allowing for more accurate border contouring in comparison to older studies. There are also important population differences- all the studies with 3T scanners are from East Asian cohorts, whereas all studies on Caucasians are with 1.5T scanners. With the presence of multiple overlapping variables, it is impossible to isolate definitively the effect of 3T vs 1.5T in this study. Previous studies dedicated to comparison of LV measures at 3T vs 1.5T have not shown significant differences between the two[39]. On balance, our judgement is that the observed differences are more likely related to ethnic differences with perhaps a smaller contribution from the various technical sources of variation.

Consistent with previous reports, we identified differences in endocardial contouring as a significant source of variation[40,41]. There was greater heterogeneity between studies that included papillary muscles within LVM compared to those that did not, perhaps reflecting difficulties in reproducibly tracing the irregular geometry of papillary muscles. Previous studies report similar variations with the potential for clinically important differences in the assessment of relevant pathologies such as hypertrophic cardiomyopathy and Fabry's disease[42,43]. Whilst other sources of technical variation do exist and perhaps have a cumulative effect, it does seem that contouring technique is the most important. Interestingly, a small study of variation of CMR derived LV measures from the use of different software packages demonstrated no significant variation from the software programmes with the application of a standardised contouring protocol and a single scanner vendor [44]. This observation suggests that the variability in LV quantification measures may be eliminated, or certainly reduced, by development of uniform contouring practices.

Our analysis suggests that the high between-study heterogeneity is a result of cumulative effects from multiple population-related and technical sources of variation. We were unable to significantly reduce between-study heterogeneity through stratification by one or two factors and the sample size does not permit meaningful sub-analysis by greater number of variables.

Relevance for clinical practice

Our results show that for both men and women, healthy young adults have on average 21% larger LVEDVi compared to healthy older adults (age <40years vs age >65years: women MD= 14.0ml/m^2, max difference= 24.3ml/m^2; men MD= 14.7 ml/m^2, max difference= 26.0 ml/m^2). Whilst specific recommendations for age-correction cannot be made, reporting cardiologists should consider this level of variation when applying reference ranges to individuals outside represented age groups. Similar considerations should be made regarding ethnicity. Our findings show lower LVMi in East Asians compared to Caucasians with mean percentage difference of 18% and 15% in men and women respectively (women: MD= 6.4g/m^2, max difference= 13.7g/m^2; men: MD=9.8g/m^2, max difference= 16.4g/m^2). These differences can be clinically important. For example, consider an East Asian man

with LVMi of 63g/m^2 – whilst this is average for a Caucasian population, it is well above the upper limit of normal for Asian cohorts (56.2g/m^2). Where possible, ethnicity-specific reference ranges should be used. Differences produced by technical factors, in particular, contouring methodology should also be considered. For instance, our findings suggest approximately 13% greater LVMi for both men and women when contouring includes papillary muscles within LVM.

Whilst CMR remains the references standard for LV quantification, the results must be interpreted with consideration of age, sex, and ethnic differences. In addition, there are multiple technical sources of variation that may result in clinically important differences in reported values. Considering the high statistical heterogeneity between studies and the importance of technical sources of variation, we would recommend use of reference ranges that most resembles one's own clinical practice in terms of image acquisition, analysis, and population. In cases of variation in practice from the reference range of choice, it is possible to making approximate corrections using the calculations provided here.

Directions for future work

This work highlights the need for richer reference datasets with attention to incorporation of data from different ethnic groups and wider spectrum of ages. The lack of published data from ethnicities with known important differences in cardiac morphology, in particular African populations, is a significant limitation of existing literature. We should aim for development of reference ranges that are fully stratified by age, sex, and ethnicity. It is also important that we reduce the level of heterogeneity introduced by technical factors, with development of a unified approach to contouring methodology being a key step. However, it is difficult to make consensus recommendations at present, as it is not clear from existing literature, which contouring method best predicts clinical outcomes and/or discriminates disease. Therefore, prior to embarking on development of standardised approaches, research is needed into the prognostic and diagnostic value of different contouring methodologies. Finally, consideration of variability in cardiac morphometrics beyond traditional CMR indices is important for better understanding of differential disease patterns and risk profiles in different populations and would allow for deeper phenotyping of individuals and their disease susceptibilities.

Limitations

Our search strategy was thorough for published reports of CMR normal reference ranges; however, we did not seek results from unpublished cohorts. Whilst this may have resulted in a larger sample size, quality control of data that has not been through a formal peer review process is challenging and inclusion of such data may have compromised the quality of the study. There are important gaps in the literature with paucity of data for individuals in the youngest and oldest age categories and limited representation of non-Caucasian ethnicities. Our analysis reflects these gaps in published data. Whilst age, sex, and ethnicity explain part of the between-study heterogeneity, there are technical sources of variation that cannot be fully explored within the scope of this study (Figure 4).

Conclusions

There is significant heterogeneity in published CMR LV reference ranges. Age, sex, and ethnicity represent significant sources of variation and we should endeavour to develop reference ranges stratified to these parameters. Different endocardial contouring methodology, scanner magnet strength, and post-processing software all contribute to the observed variability. Due to multiple sources of heterogeneity, it is not possible to produce reliable normal ranges across a wide age range, by sex or ethnicity from existing reports. Wider representation of different populations and standardisation of image analysis is urgently needed to establish such reference distributions, and thus ensure global comparability of CMR measures.

Acknowledgements

ZRE is supported by a British Heart Foundation Clinical Research Training Fellowship (FS/17/81/33318). NA is supported by a Wellcome Trust Research Training Fellowship (203553/Z/16/Z). SEP acknowledges support from the National Institute for Health Research (NIHR) Cardiovascular Biomedical Research Centre at Barts NHS Trust and has received funding from the European Union's Horizon 2020 research and innovation programme (825903). SEP acts as a paid consultant to Circle Cardiovascular Imaging Inc., Calgary, Canada and Servier. NCH has received

consultancy, lecture fees, and honoraria from Alliance for Better Bone Health, Amgen, MSD, Eli Lilly, Servier, Shire, Radius Health, UCB, Consilient Healthcare, Kyowa Kirin and Internis Pharma.

References

1. Gjesdal O, Bluemke DA, Lima JA. Cardiac remodeling at the population level—risk factors, screening, and outcomes. *Nat Rev Cardiol* 2011;**8**:673–685.
2. Leonardi S, Raineri C, Ferrari GM De, Ghio S, Scelsi L, Pasotti M, et al. Usefulness of cardiac magnetic resonance in assessing the risk of ventricular arrhythmias and sudden death in patients with hypertrophic cardiomyopathy. *Eur Heart J* 2009;**30**:2003–2010.
3. Bluemke DA, Kronmal RA, Lima JAC, Liu K, Olson J, Burke GL, et al. The Relationship of Left Ventricular Mass and Geometry to Incident Cardiovascular Events. *J Am Coll Cardiol* 2008;**52**:2148–2155.
4. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic Implications of Echocardiographically Determined Left Ventricular Mass in the Framingham Heart Study. *N Engl J Med* 1990;**322**:1561–1566.
5. Cleland JGF, Daubert J-C, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure. *N Engl J Med* 2005;**352**:1539–1549.
6. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, Marco T De, et al. Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart Failure. *N Engl J Med* 2004;**350**:2140–2150.
7. Taniguchi T, Morimoto T, Shiomi H, Ando K, Kanamori N, Murata K, et al. Prognostic Impact of Left Ventricular Ejection Fraction in Patients With Severe Aortic Stenosis. *JACC Cardiovasc Interv* 2018;**11**:145–157.
8. McMurray JJV. Systolic Heart Failure. *N Engl J Med* 2010;**362**:228–238.
9. Aurigemma GP, Gaasch WH. Diastolic Heart Failure. *N Engl J Med* 2004;**351**:1097–1105.
10. Petersen SE, Khanji MY, Plein S, Lancellotti P, Bucciarelli-Ducci C. European Association of Cardiovascular Imaging expert consensus paper: a comprehensive review of cardiovascular

magnetic resonance normal values of cardiac chamber size and aortic root in adults and recommendations for grading severity. *Eur Heart J Cardiovasc Imaging* 2019;**44**:1–11.

11. Kishi S, Reis JP, Venkatesh BA, Gidding SS, Armstrong AC, Jacobs DR, et al. Race-ethnic and sex differences in left ventricular structure and function: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. *J Am Heart Assoc* 2015;**4**:e001264.
12. Strait JB, Lakatta EG. Aging-associated cardiovascular changes and their relationship to heart failure. *Heart Fail Clin* 2012;**8**:143–164.
13. Forman DE, Cittadini A, Azhar G, Douglas PS, Wei JY. Cardiac Morphology and Function in Senescent Rats: Gender-Related Differences. *J Am Coll Cardiol* Elsevier; 1997;**30**:1872–1877.
14. Kawel-Boehm N, Maceira A, Valsangiacomo-Buechel ER, Vogel-Claussen J, Turkbey EB, Williams R, et al. Normal values for cardiovascular magnetic resonance in adults and children. *J Cardiovasc Magn Reson* 2015;17–29.
15. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* 2016;**355**:i4919.
16. Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2 Group. QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies. *Ann Intern Med* 2011;**155**:529.
17. Schwarzer G. meta: An R Package for Meta-Analysis. *R News* 2007;**7**:40–46.
18. Li CY, Gao BL, Guo FQ, Zhang XJ, Fan QY, Wu BL, et al. Quantitative evaluation of left ventricular volume and function in middle-aged healthy chinese people with 3 Tesla MRI. *J Magn Reson Imaging* 2016;**44**:1143–1150.
19. Lei X, Liu H, Han Y, Cheng W, Sun J, Luo Y, et al. Reference values of cardiac ventricular structure and function by steady-state free-procession MRI at 3.0T in healthy adult chinese volunteers. *J Magn Reson Imaging* 2017;**45**:1684–1692.
20. Le TT, Tan RS, De Deyn M, Goh EPC, Han Y, Leong BR, et al. Cardiovascular magnetic resonance reference ranges for the heart and aorta in Chinese at 3T. *J Cardiovasc Magn Reson*; 2016;**18**:21.

21. Chang SA, Choe YH, Jang SY, Kim SM, Lee SC, Oh JK. Assessment of left and right ventricular parameters in healthy Korean volunteers using cardiac magnetic resonance imaging: change in ventricular volume and function based on age, gender and body surface area. *Int J Cardiovasc Imaging* 2012;**Suppl2**:141–147.

22. Macedo R, Fernandes JL, Andrade SS, Rochitte CE, Lima KC, Maciel ÁCC, et al. Morphological and Functional Measurements of the Heart Obtained by Magnetic Resonance Imaging in Brazilians. *Arq Bras Cardiol* 2013;**101**:68–77.

23. Bülow R, Ittermann T, Dörr M, Poesch A, Langner S, Völzke H, et al. Reference ranges of left ventricular structure and function assessed by contrast-enhanced cardiac MR and changes related to ageing and hypertension in a population-based study. *Eur Radiol* R. 2018;**28**:3996–4005.

24. Petersen SE, Aung N, Sanghvi MM, Zemrak F, Fung K, Paiva JM, et al. Reference ranges for cardiac structure and function using cardiovascular magnetic resonance (CMR) in Caucasians from the UK Biobank population cohort. *J Cardiovasc Magn Reson* 2017;**19**:18.

25. Aquaro GD, Camastra G, Monti L, Lombardi M, Pepe A, Castelletti S, et al. Reference values of cardiac volumes, dimensions, and new functional parameters by MR: A multicenter, multivendor study. *J Magn Reson Imaging* 2017;**45**:1055–1067.

26. Ven F Le, Bibeau K, Larochelliere E De, Tizon-Marcos H, Deneault-Bissonnette S, Pibarot P, et al. Cardiac morphology and function reference values derived froma large subset of healthy young Caucasian adults by magnetic resonance imaging. *Eur Heart J Cardiovasc Imaging* 2016;**17**:981–990.

27. Yeon SB, Salton CJ, Gona P, Chuang ML, Blease SJ, Han Y, et al. Impact of age, sex, and indexation method on MR left ventricular reference values in the framingham heart study offspring cohort. *J Magn Reson Imaging* 2015;**41**:1038–1045.

28. Teo KSL, Carbone A, Piantadosi C, Chew DP, Hammett CJK, Brown MA, et al. Cardiac MRI Assessment of Left and Right Ventricular Parameters in Healthy Australian Normal Volunteers. *Hear Lung Circ* 2008;**17**:313–317.

29. Maceira AM, Prasad SK, Khan M, Pennell DJ. Normalized left ventricular systolic and

diastolic function by steady state free precession cardiovascular magnetic resonance. *J Cardiovasc Magn Reson* 2006;**8**:417–426.

30. Hudsmith LE, Petersen SES, Francis JJM, Robson MDM, Neubauer S. Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. *J Cardiovasc Magn Reson* 2005;**7**:775–782.
31. Lin FY, Devereux RB, Roman MJ, Meng J, Jow VM, Jacobs A, et al. Cardiac Chamber Volumes, Function, and Mass as Determined by 64-Multidetector Row Computed Tomography: Mean Values Among Healthy Adults Free of Hypertension and Obesity. *JACC Cardiovasc Imaging* 2008;**1**:782–786.
32. Chahal NS, Lim TK, Jain P, Chambers JC, Kooner JS, Senior R. Ethnicity-related differences in left ventricular function, structure and geometry: a population study of UK Indian Asian and European white subjects. *Heart* BMJ 2010;**96**:466–471.
33. Poppe KK. What is normal left ventricular ejection fraction? a global individual person data meta-analysis of the distribution across ethnicity, gender and age. *Eur Heart J* 2013;**34**:1938–1938.
34. Buccheri S, Costanzo L, Tamburino C, Monte I. Reference Values for Real Time Three-Dimensional Echocardiography-Derived Left Ventricular Volumes and Ejection Fraction: Review and Meta-Analysis of Currently Available Studies. *Echocardiography* 2015;**32**:1841–1850.
35. Natori S, Lai S, Finn JP, Gomes AS, Hundley WG, Jerosch-Herold M, et al. Cardiovascular function in multi-ethnic study of atherosclerosis: Normal values by age, sex, and ethnicity. *Am J Roentgenol* 2006;**186**:S357–S365.
36. Chaturvedi N, Athanassopoulos G, McKeigue PM, Marmot MG, Nihoyannopoulos P. Echocardiographic measures of left ventricular structure and their relation with rest and ambulatory blood pressure in blacks and whites in the United Kingdom. *J Am Coll Cardiol* 1994;**24**:1499–1505.
37. Poppe KK, Doughty RN, Gardin JM, Hobbs FDR, McMurray JJV, Nagueh SF, et al. Ethnic-Specific Normative Reference Values for Echocardiographic LA and LV Size, LV Mass, and

Systolic Function: The EchoNoRMAL Study. *JACC Cardiovasc Imaging* 2015;**8**:656–665.

38. Akintoye E, Mahmoud K, Shokr M, Sandio A, Mallikethi-Reddy S, Sheikh M, et al. Racial/ethnic differences in the prognostic utility of left ventricular mass index for incident cardiovascular disease. *Clin Cardiol* 2018;**41**:502–509.

39. Hudsmith LE, Petersen SE, Tyler DJ, Francis JM, Cheng ASH, Clarke K, et al. Determination of cardiac volumes and mass with FLASH and SSFP cine sequences at 1.5 vs. 3 Tesla: a validation study. *J Magn Reson Imaging* 2006;**24**:312–318.

40. Miller CA, Jordan P, Borg A, Argyle R, Clark D, Pearce K, et al. Quantification of left ventricular indices from SSFP cine imaging: Impact of real-world variability in analysis methodology and utility of geometric modeling. *J Magn Reson Imaging* 2013;**37**:1213–1222.

41. Suinesiaputra A, Bluemke DA, Cowan BR, Friedrich MG, Kramer CM, Kwong R, et al. Quantification of LV function and mass by cardiovascular magnetic resonance: multi-center variability and consensus contours. *J Cardiovasc Magn Reson* 2015;**17**:63.

42. Kozor R, Callaghan F, Tchan M, Hamilton-Craig C, Figtree GA, Grieve SM. A disproportionate contribution of papillary muscles and trabeculations to total left ventricular mass makes choice of cardiovascular magnetic resonance analysis technique critical in Fabry disease. *J Cardiovasc Magn Reson* 2015;**17**:22.

43. Gommans DHF, Bakker J, Cramer GE, Verheugt FWA, Brouwer MA, Kofflard MJM. Impact of the papillary muscles on cardiac magnetic resonance image analysis of important left ventricular parameters in hypertrophic cardiomyopathy. *Neth Heart J* 2016;**24**:326–331.

44. Zange L, Muehlberg F, Blaszczyk E, Schwenke S, Traber J, Funk S, et al. Quantification in cardiovascular magnetic resonance: agreement of software from three different vendors on assessment of left ventricular function, 2D flow and parametric mapping. *J Cardiovasc Magn Reson* 2019;**21**:12.

45. Bai W, Sinclair M, Tarroni G, Oktay O, Rajchl M, Vaillant G, et al. Automated cardiovascular magnetic resonance image analysis with fully convolutional networks. *J Cardiovasc Magn Reson* 2018;**20**:65.

46. Gilbert K, Bai W, Mauger C, Medrano-Gracia P, Suinesiaputra A, Lee AM, et al. Independent

Left Ventricular Morphometric Atlases Show Consistent Relationships with Cardiovascular Risk Factors: A UK Biobank Study. *Sci Rep* 2019;**9**:1130.

47. Nikitin NP, Huan Loh P, Silva R De, Witte KKA, Lukaschuk EI, Parker A,et al. Left ventricular morphology, global and longitudinal function in normal older individuals: a cardiac magnetic resonance study. *Int J Cardiol* 2006;**108**:76–83.

48. Alfakih K, Plein S, Thiele H, Jones T, Ridgway JP, Sivananthan MU. Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady-state free precession imaging sequences. *J Magn Reson Imaging* 2003;**17**:323–329.

Table 1. Summary of studies selected for inclusion in the meta-analysis

Author, year of publication	Single/Multi-centre	Sample size, Male:Female	Age*	Ethnicity	Scanner vendor	Field strength (T)	Analysis software	Contouring technique	Papillary muscle included/excluded from LVM
Bulow et al.[23], 2018	Single	*n*=617 291:326	Men (43) Women (45)	Caucasian	Siemens Magnetom	1.5	QMass MR, Medis	Manual	Included
Lei et al.[19], 2017	Single	*n*=120 60: 60	20 – 83	Chinese	Siemens Magnetom	3	QMass MR, Medis	Manual	Excluded
Petersen et al.[24], 2017	Single	*n*=800 368:432	45 – 74	Caucasian	Siemens Magnetom	1.5	CMR42, Circle Cardiovascular Imaging	Manual	Excluded
Aquaro et al.[25], 2017	Multi	*n*=255 140:115	15 – 80	Caucasian	Multi-vendor	1.5	Multiple	Manual	Included
Le et al.[20], 2016	Single	*n*=180 91:89	20 – 69	Singaporean-Chinese	Philips Ingenia	3	CMR42, Circle Cardiovascular Imaging	Not stated	Included
Li et al.[18], 2016	Single	*n*=90 45:45	40 – 65	Chinese	Philips Achieva	3	Philips Medical Systems, Philips	Manual	Included
Le Ven et al.[26], 2016	Single	*n*=434 196:238	18 – 35	Caucasian	Philips Achieva	1.5	CMR42, Circle Cardiovascular Imaging	Semi-automated	Included
Yeon et al.[27], 2015	Single	*n*=852 340:512	Men (61) Women (62)	Caucasian	Philips Gyroscan	1.5	EasyVision 5.1, Philips	Manual	Excluded
Macedo et al.[22], 2013	Multi	*n*=107 54:53	20 – 80	Brazilian	Philips Achieva	1.5	Multiple	Semi-automated	Included
Chang et al.[21], 2012	Single	*n*=124 64:60	20-70	Korean	Siemens Magnetom	1.5	Argus, Siemens	Manual	Excluded
Teo et al.[28], 2008	Single	*n*=60 41:19	51	Non-aboriginal Australian (Caucasian)	Siemens Sonata	1.5	Argus, Siemens	Manual	Included
Maceira et al.[29], 2006	Single	*n*=120 60:60	20 – 80	Caucasian	Siemens Sonata	1.5	CMRtools, Cardiovascular Imaging Solutions	Semi-automated	Included
Nikitin et al.[47], 2006	Single	*n*=95 47:48	22 – 91	Caucasian	General Electric SignaCV/i	1.5	MRI-MASS, Medis	Semi-automated	Included
Hudsmith et al.[30], 2005	Single	*n*=108 63:45	21- 68	Caucasian	Siemens Sonata	1.5	Argus, Siemens	Manual	Included
Alfakih et al.[48], 2003	Single	*n*=60 30:30	20 – 65	Caucasian	Philips Intera	1.5	MRI-MASS, Medis	Manual	Included

LVM: left ventricular mass; T: Tesla; *n* denotes total sample size available for analysis. *Age: range, or mean (years)

Table 2. Pooled mean left ventricular parameters with sex stratification and expression of between-study and subgroup heterogeneity

			Between study heterogeneity				Subgroup differences (men vs women)		
		Mean (95% CI)	Q statistic	τ^2	I^2	p-value	Mean difference	Q statistic	p-value
LVEDVi (ml/m^2)	Men	77.4 (73.7 – 81.1)	655.38	51.1	97.9%	8.5×10^{-131}	6.1	5.99	0.014
	Women	71.3 (68.1 – 74.5)	736.42	36.6	98.1%	4.3×10^{-148}			
LVESVi (ml/m^2)	Men	28.4 (25.4 – 31.3)	1196.4	29.1	99.0%	1.03×10^{-248}	4.0	4.52	0.033
	Women	24.4 (22.3 – 26.5)	933.7	14.3	98.7%	3.3×10^{-192}			
LVMi (g/m^2)	Men	60.5 (57.3 – 63.7)	773.88	18.2	98.2%	4.3×10^{-156}	12	33.32	7.8×10^{-9}
	Women	48.5 (45.9 – 51.0)	942.39	24.7	98.5%	3.5×10^{-192}			
LVEF (%)	Men	63.8 (61.6 – 66.1)	1272.22	19.2	98.9%	5.1×10^{-263}	-1.5	0.95	0.33
	Women	65.3 (63.5 – 67.1)	960.15	12.1	98.5%	5.5×10^{-196}			

CI: confidence interval; LVEDVi: left ventricular end-diastolic volume indexed to body surface area; LVESVi: left ventricular end-systolic volume indexed to body surface area; LVMi: left ventricular mass indexed to body surface area; LVEF: left ventricular ejection fraction. Significance level is set at p-value < 0.05. Random effects model is used for assessment of subgroups and between-study heterogeneity.

Figure 1. Flow diagram summarising flow of information through different phases of the systematic review



Figure 2. Forest plots of left ventricular parameters indexed to body surface area for women*



CI: confidence interval; LVEDVi: left ventricular end diastolic volume indexed to body surface area (ml/m^2); LVESVi: left ventricular end systolic volume indexed to body surface area (ml/m^2); LVMi: left ventricular mass indexed to body surface area (g/m^2); LVEF: left ventricular ejection fraction (%). Both fixed effect and random effects estimates are presented. The vertical reference line corresponds to random effects pooled mean estimate.

Figure 3. Forest plots of left ventricular parameters indexed to body surface area for men*



CI: confidence interval; LVEDVi: left ventricular end diastolic volume indexed to body surface area (ml/m^2); LVESVi: left ventricular end systolic volume indexed to body surface area (ml/m^2); LVMi: left ventricular mass indexed to body surface area (g/m^2); LVEF: left ventricular ejection fraction (%). Both fixed effect and random effects estimates are presented. The vertical reference line corresponds to random effects pooled mean estimate.

Figure 4. Potential sources of variability in cardiac magnetic resonance measurements



SSFP: steady state free precession; FOV: field of view; GE: gradient echo; LVM: left ventricular mass; SE: spin echo; TE: echo time; TR: repetition time

Figure 5. Pooled mean (95% CI) left ventricular parameters for men, stratified by age and ethnicity



LVEDVi: left ventricular end-diastolic volume indexed to body surface area (ml/m^2); LVESVi: left ventricular end-systolic volume indexed to body surface area (ml/m^2); LVEF: left ventricular ejection fraction (%); LVMi: left ventricular mass indexed to body surface area (g/m^2). Results are pooled random effects means with corresponding 95% confidence intervals (CI).

Figure 6. Pooled mean (95% CI) left ventricular parameters for women, stratified by age and ethnicity



LVEDVi: left ventricular end-diastolic volume indexed to body surface area (ml/m^2); LVESVi: left ventricular end-systolic volume indexed to body surface area (ml/m^2); LVEF: left ventricular ejection fraction (%); LVMi: left ventricular mass indexed to body surface area (g/m^2). Results are pooled random effects means with corresponding 95% confidence intervals (CI).

Central Illustration. Panel A: Sex stratified left ventricular parameters; Panel B: Age and sex stratified LVEDVi; Panel C: Ethnicity and sex stratified LVMi



LVEDVi: left ventricular end diastolic volume indexed to body surface area (ml/m^2); LVESVi: left ventricular end systolic volume indexed to body surface area (ml/m^2); LVMi: left ventricular mass indexed to body surface area (g/m^2); LVEF: left ventricular ejection fraction (%); MD: mean difference. In Panel B, MD refers to 20-40 years vs >65 years. In Panel C, Asian refers to Chinese, Singaporean-Chinese, and Korean. Displayed values are pooled random effects means from meta-analysis. Error bars correspond to 95% confidence intervals. P-value corresponds to test of heterogeneity between subgroups.

Supplementary Figure 1. Forest plots of age and sex stratified left ventricular end diastolic volume indexed to body surface area



CI: confidence interval; LVEDVi: left ventricular end diastolic volume indexed to body surface area (ml/m^2); The vertical reference line corresponds to random effects pooled mean estimate for men and women without age stratification. Vertical reference line corresponds to the pooled random effects mean for men and women without other stratification

Supplementary Figure 2. Forest plots of sex and ethnicity stratified left ventricular mass indexed to body surface area



CI: confidence interval; LVMi: left ventricular end diastolic mass indexed to body surface area (g/m^2); The vertical reference line corresponds to random effects pooled mean estimate for men and women without other stratification. Vertical reference line corresponds to the pooled random effects mean for men and women without other stratification.

Supplementary Figure 3. Forest plots of left ventricular mass indexed to body surface area stratified by sex and papillary muscle inclusion/exclusion in left ventricular mass



mean estimate for men and women without other stratification. Papillary_muscle = include indicates inclusion of papillary muscle in LVMi, papillary_muscle=exclude indicates exclusion of papillary muscles from LVMi.

Supplementary Table 1. Medline search strategy

	Search terms	**Results (*n*)**
1	exp heart ventricles/ or exp myocardium/	245485
2	exp cardiac volume/ or exp ventricular function, left/ or exp ventricular function, right/	44207
3	1 or 2	276474
4	exp Magnetic Resonance Imaging/mt, st, sn [Methods, Standards, Statistics & Numerical Data]	122759
5	exp Reference Values/	156703
6	normal.mp.	1448341
7	healthy.mp. or exp Healthy Volunteers/	671578
8	5 or 6 or 7	2094950
9	3 and 4 and 8	1159
10	limit 9 to (English language and humans and "all adult (19 plus years)")	778

Supplementary Table 2. Quality assessment of studies included in the meta-analysis

					Definition of healthy status (Exclusion criteria)	Scanning and reporting				*Score
Author, year	***n***	**Clearly defined aim**	**Data source**	**Recruitment method**		**Defined scanning protocol**	**Defined analysis protocol**	**Number of readers**	**Report observer variability?**	
Bulow et al., 2018	634	Yes	Subset of population-based study (SHIP)*	Two stage stratified cluster sampling and random cluster sampling (SHIP), subset undergoing contrast enhanced CMR included	**Cardiac disease:** MI, HF, stroke, PVD, previous cardiac surgery **CVD risk factors:** Hypertension, diabetes **Non-cardiac disease:** Chronic lung disease **Medication:** cardiovascular/pulmonary medication **Clinical assessment:** None **Blood tests**: None **Other investigations:** None	Yes	Yes	2	Inter-observer variability only	9
Lei et al., 2017	120	Yes	Not stated	Prospectively recruited volunteers without known CVD	**Cardiac disease:** Any CVD **CVD risk factors:** Hypertension **Non-cardiac disease:** None **Medication:** None **Clinical assessment:** BP >140/90mmHg **Blood tests:** Abnormal full blood count, liver/renal function **Other investigations:** Abnormal ECG/echo	Yes	Yes	Not stated	Yes	8
Petersen et al., 2017	800	Yes	Subset of population-based study (UKB)	UKB: Postal invite to all UK residents aged 20-69 years old (UKB). This study: first 5,065 UKB participants to undergo CMR	**Cardiac disease:** Any CVD **CVD risk factors:** Hypertension, diabetes, hyperlipidaemia, current/ex- smoker **Non-cardiac disease:** Respiratory haematological, renal, or rheumatological disease, malignancy **Medication:** Antihypertensives, lipid-lowering drugs, diabetic medications. **Clinical assessment:** Chest pain or dyspnoea, BMI ≥30 kg/m^2 **Blood tests:** None **Other investigations:** None	Yes	Yes	8	Yes	9
Aquaro et al., 2017	255	Yes	Not stated	Not stated	**Cardiac disease:** Any CVD **CVD risk factors:** Hypertension, diabetes, hyperlipidaemia, smoking, drug use	Yes	Yes	Not stated	Yes	8

					Non-cardiac disease: Any non-cardiac illness that may affect cardiac function **Medication:** Antihypertensives, lipid-lowering drugs **Clinical assessment:** Abnormal physical examination, BP >149/90mmHg, family history of genetic disease, BMI >30 kg/m^2 **Blood tests:** None **Other investigations:** Abnormal echo/ECG					
Le et al., 2016	180	Yes	Local community (general population)	Prospective recruitment through advertisement in local media	**Cardiac disease:** Any CVD or cerebrovascular disease **CVD risk factors:** None **Non-cardiac disease:** None **Medication:** None **Clinical assessment:** symptoms, family history of CVD or cerebrovascular disease **Blood tests:** None **Other investigations:** None	Yes	Yes	2	Inter-observer variability only	9
Li et al., 2016	90	Yes	Not stated	Not stated	**Cardiac disease:** Any CVD **CVD risk factors:** None **Non-cardiac disease:** None **Medication:** Any recent medications **Clinical assessment:** Abnormal BP (90/60 mmHg–140/90 mmHg for systolic–diastolic blood pressure, respectively) **Blood tests:** None **Other investigations:** None	Yes	Yes	Not stated	Not stated	8
Le Ven et al., 2016	434	Yes	Not stated	Phone, email, word-of-mouth invitation	**Cardiac disease:** Any CVD **CVD risk factors:** Obesity, smoking, hyperlipidaemia, diabetes **Non-cardiac disease:** None **Medication:** None **Clinical assessment:** None **Blood tests:** Abnormal lipid profile, fasting glucose, troponin, Nt-pro-BNP **Other investigations:** None	Yes	Yes	4	Yes	9

Yeon et al., 2015	852	Yes	Subset of population-based study (FHS)	FHS offspring cohort who underwent CMR	**Cardiac disease:** MI, HF **CVD risk factors:** Hypertension **Non-cardiac disease:** None **Medication:** Anti-hypertensives **Clinical assessment:** BP >140/90mmHg **Blood tests:** None **Other investigations:** None	Yes	Yes	1	Not stated	9
Macedo et al., 2013	107	Yes	Subset of LAC-CMR registry	Brazilian subset of LAC-CMR registry. Advertised on social networks, in participating universities and, private-owned clinics of the cities taking part in this study.	**Cardiac disease:** Any cardiomyopathy **CVD risk factors:** Hypertension, current/ex-smoker, diabetes **Non-cardiac disease:** None **Medication:** Anti-hypertensives **Clinical assessment:** BP (systolic > 120 mmHg or diastolic > 80 mmHg), symptoms, abnormal physical examination **Blood tests:** fasting glycemia > 100 mg/dL, total cholesterol > 200 mg/dL, abnormal BNP **Other investigations:** Abnormal ECG	Yes	Yes	3	Yes	10
Chang et al., 2012	124	Yes	Not stated	Prospective recruitment	**Cardiac disease:** Any CVD, cerebrovascular disease **CVD risk factors:** Hypertension, diabetes **Non-cardiac disease:** None **Medication:** Any regular medications **Clinical assessment:** History of chest pain or dyspnoea **Blood tests:** None **Other investigations:** Abnormal echo/ECG	Yes	Yes	1	Yes	8
Teo et al., 2008	60	Yes	Not stated	Consecutive recruitment	**Cardiac disease:** Any CVD **CVD risk factors:** Hypertension **Non-cardiac disease:** Respiratory disease **Medication:** Any regular medications **Clinical assessment:** normal BP **Blood tests:** None **Other investigations:** Abnormal echo/ECG	Yes	Yes	1	Yes	8
Maceira et al., 2006	120	Yes	Not stated	Not stated	**Cardiac disease:** Any CVD **CVD risk factors:** “Any known risk factors” **Non-cardiac disease:** None **Medication:** None	Yes	Yes	Not stated	Not stated	8

					Clinical assessment: Symptoms, abnormal physical examination **Blood tests:** Abnormal BNP **Other investigations:** Abnormal ECG					
Nikitin et al., 2006	95	Yes	Primary care practice lists	All individuals without chronic illness, CVD, or regular medication were invited	**Cardiac disease:** Any CVD **CVD risk factors:** Hypertension **Non-cardiac disease:** Any chronic illness **Medication:** None **Clinical assessment:** Blood pressure >160/95, BMI >30kg/m^2 **Blood tests:** fasting blood glucose >105 mg/dl **Other investigations:** Positive treadmill exercise test, Abnormal echo	Yes	Yes	Not stated	Not stated	8
Hudsmith et al., 2005	108	Yes	Not stated	Not stated	**Cardiac disease:** Any CVD **CVD risk factors:** Hypertension, "cardiac risk factors" **Non-cardiac disease:** None **Medication:** None **Clinical assessment:** None **Blood tests:** None **Other investigations:** Abnormal ECG	Yes	Yes	2	Yes	7
Alfakih et al., 2003	60	Yes	Not stated	Not stated	**Cardiac disease:** Any CVD **CVD risk factors:** diabetes, Hypertension **Non-cardiac disease:** None **Medication:** None **Clinical assessment:** Abnormal cardiac examination, abnormal BP **Blood tests:** None **Other investigations:** Abnormal ECG	Yes	Yes	1	Yes	7

LAC-CMR: The Latin-American, Multi-Centres, reference study of CMR (CMR-LAC Registry) ECG: electrocardiography FHS: Framingham Heart Study; SHIP: Study of Health in Pomerania; UKB: United Kingdom Biobank; CVD: cardiovascular disease; MI: myocardial infarction; ICC: intra-class correlation; COV: coefficient of variation; CMR: cardiac magnetic resonance; HF: heart failure; PVD: peripheral vascular disease; Nt-ProBNP: N terminal pro B-Type Natriuretic Peptide; *Max score =10/10

Supplementary Table 3. Pooled mean left ventricular parameters stratified by sex and age with expression of subgroup heterogeneity

		Age group (years)	*n**	Mean	95% CI	subgroup heterogeneity		
						Mean difference (20-40 years vs. >65 years)	Q statistic	p-value
LVEDVi (ml/m^2)	Women	20-40	270	79.0	(76.8 – 81.2)	14.0	18.9	8.02×10^{-5}
		40-65	880	69.7	(64.5 –74.9)			
		>65	318	65.0	(56.9 – 73.2)			
	Men	20-40	291	86.2	(82.5 – 89.8)	14.7	13.6	0.0011
		40-65	727	78.7	(73.4 – 83.9)			
		>65	247	71.5	(63.8 – 79.2)			
LVESVi (ml/m^2)	Women	20-40	257	28.7	(26.3–31.1)	6.7	5.0	0.081
		40-65	863	25.4	(21.3–29.5)			
		>65	318	22.0	(16.0–28.1)			
	Men	20-40	278	32.6	(28.5–36.7)	6.7	3.0	0.22
		40-65	710	30.1	(25.3–35.0)			
		>65	247	25.9	(19.5–32.3)			
LVMi (g/m^2)	Women	20-40	270	50.2	(44.2–56.2)	1.4	2.7	0.26
		40-65	880	45.1	(41.5–48.7)			
		>65	318	48.8	(44.0–53.7)			
	Men	20-40	291	64.3	(57.8–70.8)	4.5	1.0	0.60
		40-65	727	60.9	(56.5–65.3)			
		>65	247	59.8	(53.0–66.6)			
LVEF (%)	Women	20-40	270	63.9	(61.0–66.9)	-2.7	0.9	0.64
		40-65	880	63.6	(60.5–66.7)			
		>65	318	66.6	(61.1–72.2)			
	Men	20-40	291	62.4	(58.8–66.0)	-2.1	0.5	0.77
		40-65	727	62.2	(59.0–65.5)			
		>65	247	64.5	(59.0–70.0)			

CI: confidence interval; LVEDVi: left ventricular end diastolic volume indexed to body surface area; LVESVi: left ventricular end systolic volume indexed to body surface area; LVMi: left ventricular mass indexed to body surface area; LVEF: left ventricular ejection fraction. **n* denotes total number of participants in the pool. Results are from the random effects model.

Supplementary Table 4. Pooled mean left ventricular parameters with sex and ethnicity stratification and expression of subgroup heterogeneity

		Ethnicity	*n*	Mean (95% CI)*	Subgroup heterogeneity		
					Mean difference	Q statistic	p-value
LVEDVi (ml/m^2)	Women	Caucasian	1,825	71.7 (67.2–76.2)	3.2	1.13	0.57
		East Asian	254	70.8 (69.6–72.0)			
		Brazilian*	53	68.5 (64.3–72.2)			
	Men	Caucasian	1,576	78.4 (73.5–83.2)	4.2	1.84	0.40
		East Asian	260	75.6 (71.5–79.7)			
		Brazilian	54	74.2 (70.1–78.4)			
LVESVi (ml/m^2)	Women	Caucasian	1776	24.5 (21.4– 27.7)	0.5	0.06	0.97
		East Asian	254	24.2 (22.5–26.0)			
		Brazilian	53	24.0 (21.4–27.6)			
	Men	Caucasian	1,576	29.1 (25.2–33.0)	2.8	1.61	0.45
		East Asian	260	27.4 (23.0–31.9)			
		Brazilian	54	26.3 (24.5–28.7)			
LVMi (g/m^2)	Women	Caucasian	1,825	50.6 (47.2–54.0)	6.4	8.37	0.015
		East Asian	254	44.2 (40.3–48.1)			
		Brazilian	53	44.6 (40.5–48.5)			
	Men	Caucasian	1,576	63.4 (59.3–67.4)	9.8	18.76	8.44×10^{-5}
		East Asian	260	53.6 (51.0–56.2)			
		Brazilian	54	59.8 (55.6–63.2)			
LVEF (%)	Women	Caucasian	1,825	65.0 (62.5–67.5)	1.1	0.5	0.78
		East Asian	254	65.6 (63.0–68.2)			
		Brazilian	53	66.1 (64.9–68.6)			
	Men	Caucasian	1,576	63.8 (60.9–66.7)	1.3	0.62	0.73
		East Asian	260	63.6 (59.3–67.9)			
		Brazilian	54	64.9 (63.0–66.7)			

CI: confidence interval; LVEDVi: left ventricular end-diastolic volume indexed to body surface area (ml/m^2); LVESVi: left ventricular end-systolic volume indexed to body surface area (ml/m^2); LVMi: left ventricular mass indexed to body surface area (g/m^2); LVEF: left ventricular ejection fraction (%). Random effects estimates are presented. Asian refers to Chinese, Singaporean-Chinese, and Korean ethnicity. *The Brazilian cohort is from a single study and does not represent pooled analysis, the authors do not explicitly state ethnicity- hence we have labelled results here as "Brazilian".

Supplementary Table 5. Sensitivity analysis for LV parameters according to scanner vendor, field strength, post-processing software, and papillary muscle contouring

		Sensitivity analyses for between group differences*											
		Scanner vendor		Magnet strength		Post-processing software		Contouring methodology		Age		Ethnicity	
		Q	p-value	Q	p-value	Q	p-value	Q	p-value	Q	p-value	Q	p-value
LVEDVi (ml/m^2)	Men	0.44	0.51	0.47	0.49	5.01	0.29	0.19	0.67	**13.62**	**0.0011**	0.73	0.39
	Women	0.28	0.60	0.22	0.64	1.80	0.77	0.43	0.51	**18.86**	**8.02×10^{-5}**	0.15	0.69
LVESVi (ml/m^2)	Men	0.44	0.51	0.03	0.86	**27.36**	**1.14×10^{-6}**	0.85	0.36	3.01	0.22	0.3	0.58
	Women	0.7	0.40	0.01	0.94	**10.87**	**0.012**	0.2	0.66	5.04	0.081	0.03	0.86
LVMi (g/m^2)	Men	0.28	0.60	**26.55**	**2.6×10^{-7}**	**183.48**	**1.6×10^{-39}**	**5.71**	**0.017**	1.02	0.60	**15.88**	**6.7×10^{-5}**
	Women	1.03	0.31	**4.28**	**0.039**	**8.09**	**0.044**	**4.77**	**0.029**	2.68	0.26	**5.85**	**0.016**
LVEF (%)	Men	0.45	0.50	0.07	0.80	6.49	0.17	1.41	0.23	0.53	0.77	0	0.95
	Women	0.71	0.40	0.02	0.89	6.51	0.16	0.53	0.47	0.91	0.64	0.1	0.75

*scanner vendor (Siemens, Philips), field strength (1.5T, 3T), post-processing software [CMR42 (Circle Cardiovascular imaging, Qmass (Medis), MRI-mass (Medis), Argus(Siemens)], and contouring methodology (papillary muscles included vs excluded from LVM). CI: confidence interval; LVEDVi: left ventricular end diastolic volume indexed to body surface area (ml/m^2); LVESVi: left ventricular end systolic volume indexed to body surface area (ml/m^2); LVMi: left ventricular mass indexed to body surface area (g/m^2); LVEF: left ventricular ejection fraction (%). Results are based on random effects estimates. significance level is set at p-value <0.05.